Drugs / RUSERONTINIB
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05072522 | Oct 2021 → Oct 2023 | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05369858 | Aug → Sep 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05070195 | Jun → Jul 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05069870 | Jun → Nov 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05109663 | Apr → Jun 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02859948 | May 2016 → Dec 2017 | acute myeloid leukemia | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05445154 | Aug 2021 → Oct 2024 overdue | acute myeloid leukemia | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04015024 | Jul 2019 → Apr 2021 | acute myeloid leukemia | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04716114 | Mar 2021 → Dec 2025 | acute myeloid leukemia | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-02-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - THE GROUP'S ONCOLOGY DRUG "SKLB1028 CAPSULES" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗
THE GROUP’S ONCOLOGY DRUG “SKLB1028 CAPSULES” WAS GRANTED CLINICAL TRIAL APPROVAL |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-02-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - THE GROUP'S ONCOLOGY DRUG "SKLB1028 CAPSULES" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUSERONTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3678958 ↗ |
| Known as | SKLB1028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05070195 ↗ |
| Action | Inhibit | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL3678958 ↗2“Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL3678958 ↗ “Tyrosine-protein kinase ABL inhibitor” CHEMBL3678958 ↗ |
| Modality | Small molecule | — CHEMBL3678958 ↗ |
| Route | Oral | “Patients will receive oral SKLB1028 for 28 days” NCT02859948 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL3678958 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL3678958 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL3678958 ↗ |